Novartis | NOVN - Assets



Novartis reported $104.4B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Alcon AG USD 31.39B 379M Jun/2025
Almirall EUR 2.31B 88.18M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Autolus Therapeutics Ltd 720.98M 25.36M Jun/2025
Bayer EUR 105.24B 3.95B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Fresenius EUR 41.32B 1.89B Jun/2025
Fresenius Medical Care EUR 31.29B 1.44B Jun/2025
Galapagos EUR 3.82B 203.72M Jun/2025
Genmab DKK 6.46B 122M Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
GRIFOLS EUR 19.77B 1.21B Jun/2025
Hikma Pharmaceutical USD 5.13B 286M Dec/2024
J&J USD 193.67B 13.57B Mar/2025
Lonza CHF 19.73B 1.85B Dec/2024
Merck EUR 47.35B 2.02B Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Novartis USD 104.4B 2.15B Jun/2025
Novo Nordisk 482.15B 7.01B Jun/2025
Orion EUR 1.65B 56M Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Philips EUR 26.38B 788M Jun/2025
Recordati EUR 5.18B 9.99M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sanofi 124.96B 6.93B Jun/2025
UCB EUR 17.35B 1.72B Dec/2024